Pharma Focus Asia

WuXi Biologics Announces Manufacturing Partnership with InflaRx

Tuesday, May 16, 2023

WuXi Biologics announced the manufacturing partnership with InflaRx for its COVID-19 treatment Gohibic (vilobelimab).

Under the terms of the agreement, WuXi Biologics will provide cGMP manufacturing of Gohibic, a first-in-class monoclonal anti-human complement factor C5a antibody.

The partnership represents another remarkable efforts to establish a robust manufacturing network on a global scale. Together this collaboration aims to ramp up production under high pressure to roll out supply in order to serve the patient population in need as soon as possible. With its advanced technology and proven expertise, WuXi Biologics greatly helped apply to the FDA for emergency use approval of Gohibic.

With a global manufacturing network that includes facilities in the United States, Ireland, Germany, China and Singapore, WuXi Biologics leverages its development and manufacturing technologies to provide more efficient and cost-effective production of drug substances (DS) and drug products (DP), delivering commercial biologics for global clients and enabling promising treatments delivered to patients worldwide.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024